Search clinical trials for: FP-01.1-Adjuvant TIV

Total 327 results

Immune Targeting Systems Ltd

Completed

Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults

Influenza A
Immune Targeting Systems Ltd
INCResearch Australia Pty Limited

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)

Influenza A

Australia
Immune Targeting Systems Ltd
Hammersmith Medicines Research

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza A Vaccine

Influenza

United Kingdom
Immune Targeting Systems Ltd

Completed

Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge

Influenza A

United Kingdom
Judit Pich Martínez

Completed

A Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy

HIV-infection

Spain
Altimmune, Inc.

Completed

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

Hepatitis B

Korea, Republic of, United Kingdom
PATH
GlaxoSmithKline; Icahn School of Medicine at Mount Sinai; Duke University; Children... and other collaborators

Completed

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

Influenza | Vaccine

United States
Fluart Innovative Vaccine Ltd, Hungary

Completed

Safety of 4Fluart ID Suspension for Injection in Adult Subjects

Human Influenza

Hungary
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (DPIV-001)

Dengue Fever

United States
BiondVax Pharmaceuticals ltd.

Completed

A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers

Influenza

Israel
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); Department of Health and Human Services

Suspended

A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

HIV

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) (DPIV-002)

Dengue Fever

Puerto Rico
Faron Pharmaceuticals Ltd
Seventh Framework Programme

Terminated

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS) (INTEREST)

Respiratory Distress Syndrome, Adult

Spain, United Kingdom, France, Italy, Finland, Czechia, Belgium, Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

Influenza

United States, Colombia, Panama, Philippines
Novavax

Completed

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

Respiratory Syncytial Virus (RSV)

United States
Seqirus
Novartis Vaccines

Completed

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

Influenza Virus

United States, Canada, Finland, Italy, Mexico, Philippines, Poland, Puerto Rico, Spain, Taiwan, Thailand
Leiden University Medical Center
Göteborg University; Walter Reed Army Institute of Research (WRAIR); PATH; European... and other collaborators

Not yet recruiting

InvaplexAR-Detox and dmLT Adjuvant in the Netherlands and Zambia (SUNSHINE)

Shigellosis | Bacillary Dysentery

Netherlands
Insight Therapeutics, LLC
Brown University; Case Western Reserve University; Seqirus

Completed

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Influenza | Influenza-like Illness

United States
TVAX Biomedical

Completed

Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

Glioblastoma Multiforme | Grade IV Astrocytoma | Grade IV Glioma

United States
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
TVAX Biomedical

Available

TVI-Brain-1 in Expanded Access Patient

Recurrent Glioblastoma

United States
Seqirus

Completed

Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)

Influenza

Finland, Philippines, Thailand
Topivert Pharma Ltd

Completed

Study of TOP1630 for Dry Eye Syndrome (THEIA-1)

Dry Eye Syndrome

United States
National Cancer Institute (NCI)

Completed

Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects (FBP00004)

Healthy Volunteers | Influenza Immunisation

United States
University of Illinois at Chicago
National Cancer Institute (NCI)

Completed

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
BiondVax Pharmaceuticals ltd.

Completed

Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)

Influenza

Israel
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
BiondVax Pharmaceuticals ltd.

Completed

A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers

Healthy | Influenza

Israel
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults

HIV Infections

United States, Brazil
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment

Melanoma (Skin)

United States
US Department of Veterans Affairs
St. Louis University

Withdrawn

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly (CCTA #0005)

Aged | Influenza Vaccines

United States
Janssen Vaccines & Prevention B.V.

Completed

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults (IPCAVD-012)

Healthy

United States, Rwanda, Kenya
Seqirus

Completed

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Influenza, Human

United States
St George's, University of London
Novartis Vaccines; European Union; Richmond Pharmacology Limited

Terminated

Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63

HIV Infections

United Kingdom
Universitair Ziekenhuis Brussel

Not yet recruiting

A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma (NEO-GLITIPNI)

Recurrent Glioblastoma

Belgium
Bill & Melinda Gates Medical Research Institute
Iqvia Pty Ltd

Withdrawn

Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water Emulsion

Influenza
U.S. Army Medical Research and Development Command

Completed

TDENV PIV and LAV Dengue Prime-boost Strategy

Dengue

United States
National Cancer Institute (NCI)

Terminated

p53 Vaccine for Ovarian Cancer

Ovarian Neoplasm

United States
Jin Yuan

Unknown

Correlation of Noninvasive Tear Film Function and the Optical Quality in Mild and Moderate Dry Eye

Dry Eye | Tear Film Insufficiency

China
International AIDS Vaccine Initiative
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines

HIV Infections

Kenya, Zambia, Uganda
Academisch Medisch Centrum - Universiteit van Amsterdam...

Completed

Amsterdam UMC Clinical Trial With a Native-like HIV-1 Envelope Vaccine (ACTHIVE-001)

HIV-1-infection

Netherlands
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP

HIV Infections

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

Dengue

United States

3

Subscribe